| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_916075766043ce900399a4c2eee9f054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed3c349a8aa75c257d28b6b1c7b978b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_523275362db260511bdc01a53bacb824 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-741 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74 |
| filingDate |
2021-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1317f06249295f5815ac40bd49a765d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d460320baa38db374b7e4ec897c1c59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d3c31bd1f34faa722869a29c94bd496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_562aabd9422530592e05933ca47dd8ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54a15b34430af0c0e32336442223146e |
| publicationDate |
2021-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021163490-A1 |
| titleOfInvention |
Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion |
| abstract |
This disclosure provides transgenic Gram-negative bacteria characterized by a functional type VI secretion system and which expresses at least one heterologous affinity reagent that specifically binds a surface antigen on a target Gram-negative bacterium. In an illustrative embodiment, the affinity reagent is a single-domain antibody (nanobody). The target bacterium is typically a different species or strain from the transgenic bacterium. The surface antigen can be characterized as substantially unique to the target bacterium, e.g., within the context of a heterologous population (e.g., a gut microbiota). Also disclosed are related compositions (e.g., probiotic compositions) and method for treatment and selective depletion of target Gram-negative bacterium from a variety of environments. |
| priorityDate |
2020-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |